Redmile Group IGMS Position
ExitedRedmile Group exited their position in IGM Biosciences Inc. (IGMS) in Q3 2025, after holding the stock for 11 quarters.
The position was first reported in Q1 2023 and has been tracked across 11 quarterly 13F filings.
2 other tracked funds also hold IGMS.
About IGM Biosciences Inc.
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. It has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
Full company profile →Redmile Group IGMS Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q3 2025 | Exited | 0 | -2,952,131 | $0 |
| Q2 2025 | Held | 2,952,131 | — | $3.3M |
| Q1 2025 | Held | 2,952,131 | — | $3.4M |
| Q4 2024 | Decreased | 2,952,131 | -120,347 | $18.0M |
| Q3 2024 | Held | 3,072,478 | — | $50.8M |
| Q2 2024 | Held | 3,072,478 | — | $21.1M |
| Q1 2024 | Increased | 3,072,478 | +100,936 | $29.6M |
| Q4 2023 | Held | 2,971,542 | — | $24.7M |
| Q3 2023 | Held | 2,971,542 | — | $24.8M |
| Q2 2023 | Decreased | 2,971,542 | -362,813 | $27.4M |
| Q1 2023 | New | 3,334,355 | +3,334,355 | $45.8M |
Frequently Asked Questions
Does Redmile Group own IGMS?
No. Redmile Group exited their position in IGM Biosciences Inc. (IGMS) in Q3 2025. They previously held the stock for 11 quarters.
How many hedge funds own IGMS?
2 specialist biotech hedge funds currently hold IGMS, including Baker Bros. Advisors, RA Capital Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Redmile Group first buy IGMS?
Redmile Group's position in IGMS was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Redmile Group's IGMS position increasing or decreasing?
Redmile Group completely exited their IGMS position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
IGMSCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Redmile GroupPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →